Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.40 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415704 | 0.98 | PTGDR2 (0.72) | PTGDR2TBXA2RPTGDRMEN1FFAR1 | |
| SCHEMBL12415798 | 0.98 | PTGDR2 (0.69) | PTGDR2TBXA2RPTGDRMEN1FFAR1 | |
| SCHEMBL12415712 | 0.95 | PTGDR2 (0.79) | PTGDR2TBXA2RPTGDRMEN1FFAR1 | |
| SCHEMBL12415711 | 0.95 | PTGDR2 (0.79) | PTGDR2TBXA2RPTGDRMEN1FFAR1 | |
| SCHEMBL12415714 | 0.95 | PTGDR2 (0.79) | PTGDR2TBXA2RPTGDRMEN1FFAR1 | |
| SCHEMBL12415725 | 0.95 | PTGDR2 (0.79) | PTGDR2TBXA2RPTGDRMEN1FFAR1 | |
| SCHEMBL12415718 | 0.95 | PTGDR2 (0.79) | PTGDR2TBXA2RPTGDRMEN1FFAR1 | |
| SCHEMBL12415717 | 0.95 | PTGDR2 (0.79) | PTGDR2TBXA2RPTGDRMEN1FFAR1 | |
| SCHEMBL10024778 | 0.95 | PTGDR2 (0.79) | PTGDR2TBXA2RPTGDRMEN1FFAR1 | |
| SCHEMBL12415729 | 0.95 | PTGDR2 (0.79) | PTGDR2TBXA2RPTGDRMEN1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541419-B2 | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists | ACTIMIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | GB005, INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH4 | PTGDR2 87/4885TBXA2R 115/4885PTGDR 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.